DSP Healthcare Fund Direct Growth
NAV as on 01-04-2025
₹ 40.34
1D
Inception Returns
24.6%
/yr
Historical NAV & Returns
Absolute
▲
▼
9016 people have invested ₹ 2.7Cr in DSP Healthcare Fund Direct Growth in the last three months
About DSP Healthcare Fund Direct Growth
DSP Healthcare Fund Direct Growth is an equity fund. This fund was started on 30 November, 2018. The fund is managed by Chirag Dagli. The fund could potentially beat inflation in the long-run.
Key Parameters
- DSP Healthcare Fund Direct Growth has ₹3198 Cr worth of assets under management (AUM) as on Feb 2025 and is more than category average.
- The fund has an expense ratio 0.6.
Returns
DSP Healthcare Fund Direct Growth has given a CAGR return of 24.63% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 12.76%, 20.35% and 29.80% respectively.
Holdings
DSP Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Financial Services. Its top holdings are Suven Pharmaceuticals Ltd, Sun Pharmaceuticals Industries Ltd, Cipla Ltd, Ipca Laboratories Ltd, Globus Medical Inc Class A
Taxation
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 20%For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefitDividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.
Investment objective of DSP Healthcare Fund Direct Growth
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. However, there can be no assurance that the investment objective of the scheme will be realized.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 100.00 and for SIP is INR 100.00. DSP Healthcare Fund Direct Growth has no lock in period.
DSP Healthcare Fund Direct Growth Overview
| Expense ratio | 0.63% |
Benchmark | S&P BSE Healthcare PR |
| AUM | ₹3198 Cr |
| Inception Date | 30 November, 2018 |
| Min Lumpsum/SIP | ₹100/₹100 |
Exit Load | 0.5% |
| Lock In | No Lock-in |
TurnOver | 17.89% |
| STCG | Selling mutual fund before 1 year, returns taxed at 20%. |
| LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
| Risk |   Very High Risk |
INDmoney Rank for DSP Healthcare Fund Direct Growth
Powered by IND quant engine
IND ranking is not available for this fund.
3Y returns in the top 25% of the category
Among most bought funds within the category
Beats FD returns for both 3Y & 5Y duration
No bad points found for this fund.
Trailing Returns
as on (01-Apr-25)
Fund Distribution
as on (28-Feb-25)
Small cap
49.6%
Large cap
18.7%
Mid cap
13.9%
Sector Allocation
Health
98.6%
Financial Services
1.4%
All changes are between Dec'24 and Feb'25
- AUM of the fund stands at 3.2K Cr as of Feb'25
- AUM has remained same between Feb'25 and Jan'25
Top Stocks bought last month
Ipca Laboratories Ltd's allocation increased from 5.26% to 7.37%
Suven Pharmaceuticals Ltd's allocation increased from 8.21% to 10.25%
Gland Pharma Ltd's allocation increased from 4.39% to 4.84%
Top Stocks sold last month
Sun Pharmaceuticals Industries Ltd's allocation decreased from 10.23 % to 10.13 %
Globus Medical Inc Class A's allocation decreased from 6.75 % to 6.39 %
Illumina Inc's allocation decreased from 5.77 % to 4.22 %
Top 2 Sectors in February were Health, Financial Services
Feb'25
Health
99%
Financial Services
1%
Jan'25
Health
99%
Financial Services
1%
Holdings | Weight% | 1M Change | |
|---|---|---|---|
 Suven Pharmaceuticals Ltd | 10.25% | 0% | |
 Sun Pharmaceuticals Industries Ltd | 10.13% | 0% | |
 Cipla Ltd | 8.54% | 0% | |
 Ipca Laboratories Ltd | 7.37% | 0% | |
 Globus Medical Inc Class A | 6.39% | 0% |
See all
See all
Top Growth Drivers | 1M Return |
|---|---|
 Alembic Pharmaceuticals Ltd | 24.9% |
 Ipca Laboratories Ltd | 10.8% |
 Sun Pharmaceutical Industries Ltd | 9.4% |
Loading...
We are taking more time than usual
Chirag Dagli
Fund Manager of DSP Healthcare Fund Direct Growth, since 1 December 2020
Top funds managed
Fund House
DSP Asset Managers Private Limited
Total Schemes
Total AUM
₹1.28L Cr
as on 30-Sep-2023
Address
India
Phone
91-22-66578000
Website
service@dspblackrock.com
Mutual Fund Insights
Over the last 6 months, this fund has experienced a 9.0% growth in AUM moving from 2.93K Cr to 3.19K Cr.
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 0.63% which is lower than the category average expense ratio of 1.41%.
In the last 3 years, SBI Healthcare Opportunities Fund Direct Growth has given 23.57% return, outperforming this fund by 3.22% per annum.
In the last 1 year, HDFC Pharma and Healthcare Fund Direct Growth has given 27.72% return, outperforming this fund by 14.96%.
Over the last 1 year, this fund has decreased expense ratio by 8.7% moving from 0.69 to 0.63.
In the last 5 years, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 31.78% return, outperforming this fund by 1.98% per annum.
DSP Healthcare Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 24.63% since inception which is more than its category average return of 16.54%
Fund Allocations
This fund has an allocation of 98.27% in Equity, 0% in Debt and 1.73% in Cash related instruments
AUM size ₹3198 Cr
This fund has AUM of ₹3198 Cr which is more than its category average of ₹ 1725 Cr
Expense Ratio 0.63%
This fund has an expense ratio of 0.63% which is less than its category average expense ratio of 1.45%
Most Popular Comparisons
- Compare
DSP Healthcare FundVs
Nippon India Pharma Fund Direct Growth
- Compare
- DSP Healthcare FundVs
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
- Compare
- DSP Healthcare FundVs
SBI Healthcare Opportunities Fund Direct Growth
- Compare
- DSP Healthcare FundVs
Mirae Asset Healthcare Fund Direct Growth
- Compare
- DSP Healthcare FundVs
UTI Healthcare Fund Direct Growth
More funds from DSP
DSP India T.I.G.E.R. Fund - Direct Plan - Growth
5Y CAGR
▲ 37.87
DSP Equity Opportunities Fund Direct Plan Growth
5Y CAGR
▲ 29.73
DSP ELSS Tax Saver Fund Direct Plan Growth
5Y CAGR
▲ 30.54
DSP Top 100 Equity Fund Direct Plan Growth
5Y CAGR
▲ 25.29
DSP Focus Fund Direct Plan Growth
5Y CAGR
▲ 25.66
Frequently Asked Questions for DSP Healthcare Fund Direct Growth
The current NAV of DSP Healthcare Fund Direct Growth is ₹40.34 as on 01-Apr-2025.
Existing (Absolute + CAGR) as on 01-Apr-2025.
DSP Healthcare Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | 1.76% | 1.76% |
6 Month Returns | -9.36% | -9.36% |
1 Year Returns | 12.76% | 12.76% |
3 Years Returns | 74.33% | 20.35% |
5 Years Returns | 268.45% | 29.8% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
0.63% as on March 2025
₹3198 Cr as on March 2025
Suven Pharmaceuticals Ltd(10.25%), Sun Pharmaceuticals Industries Ltd(10.13%), Cipla Ltd(8.54%), Ipca Laboratories Ltd(7.37%), Globus Medical Inc Class A(6.39%) as on March 2025
The alpha ratio for the DSP Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
DSP Healthcare Fund Direct Growth | -1.02 | 2.42 | 5.1 |
As on March 2025
The alpha for DSP Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the DSP Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
DSP Healthcare Fund Direct Growth | 0.84 | 0.87 | 0.8 |
As on March 2025
The Beta for DSP Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the DSP Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
DSP Healthcare Fund Direct Growth | 0.52 | 0.9 | 1.32 |
As on March 2025
The sharpe ratio for DSP Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the DSP Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
DSP Healthcare Fund Direct Growth | 18.3 | 15.95 | 17.06 |
As on March 2025
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.62 as on March 2025. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.16 as on March 2025. It tells the consistency of the fund in generating superior risk-adjusted performance
Chirag Dagli is the fund manager of DSP Healthcare Fund Direct Growth
The Exit load of DSP Healthcare Fund Direct Growth is 0.5%